SBA Advocacy Office Joins Industry In Opposing AER Labeling Guidance
This article was originally published in The Tan Sheet
FDA should "better analyze the possible effects" its adverse event reporting draft guidance will have on the dietary supplement industry, according to the Small Business Administration's independent Office of Advocacy
You may also be interested in...
FDA's estimate of nearly $44 million for the dietary supplement industry to revise labels to comply with the adverse event reporting law may understate the actual burden by leaving out some key costs
FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations
As dietary supplement firms revise their product labels to reflect FDA's adverse event reporting draft guidance, some industry experts say acceptable changes are not as onerous as many have feared